Britain and America have signed a significant commercial pact that will guarantee zero tariffs on British pharmaceutical products being sold in the US market.
Key Provisions of the Deal
In exchange for the tariff guarantee, the UK has committed to boost expenditure on drugs through the NHS. This pledge secures that duties on these key exports will stay at zero for a period of three years.
This agreement comes after earlier statements to significantly raise tariffs on branded drug products, with increases discussed as high as double the cost.
"This deal between the United Kingdom bolsters the international landscape for innovative medicines and introduces long-overdue balance to U.S.–U.K. drug exports," a release said.
Trade Importance
Medicines represent one of the the United Kingdom's largest export categories to the United States, which is by far the biggest market for major companies like GSK and AstraZeneca.
Statistics reveal that in the 12 months prior to last September, the UK shipped drugs valued at billions to the US. This value represented a significant portion of British export trade in that period.
"This agreement safeguards employment, increases capital expenditure and paves the way for the UK to become a worldwide center for medical research," the Business and Trade Secretary stated.
Specific NHS Changes
The deal involves several key changes from the UK:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it considers new therapies to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a target to raise total health service expenditure on treatments from 0.3% of the national economy to 0.6% over the next decade.
- Payback Limit: The sum drug companies must refund to the NHS to prevent overspending will be limited at 15%. Previously, rebates topped 20%.
Broader Context
The pact comes amid a ongoing dispute between the drug companies and the British authorities over drug pricing and approval rates.
These tensions were intensified by arguments that US patients were paying significantly more for the identical medicines than consumers in the other developed nations.
Over the last 18 months, several major manufacturing plans in the UK have been paused or scrapped, while major investments have been directed toward projects in the United States.
The Science Minister publicly accepted that the NHS must increase expenditure on drugs, noting that its budget allocation on drugs had declined as a percentage of its overall budget over the past decade.
